Vaccinproduktion hotas av exportförbud: Oroväckande
Vaccinproduktionen i Europa hotas när andra länder inför exportförbud på material eller reservdelar som behövs för tillverkningen, rapporterar Ekot. Att exempelvis USA har ett brett exportförbud kan få konsekvenser för Europas vaccintillgång i framtiden.
– Det kan ställa till det om våra fabriker i Europa inte kan bli försörjda med reservdelar, säger vaccinsamordnaren Richard Bergström till radion.
Europa är i stort sett självförsörjande på mRNA-vaccin men på sikt kan det bli problem med reservdelar, säger Bergström.
– Jag tycker att det är oroväckande att länder stänger gränserna för en sådan viktig sak som vacciner.
bakgrund
mRNA-vaccin
Wikipedia (en)
An RNA vaccine or mRNA (messenger RNA) vaccine is a type of vaccine that uses a copy of a natural chemical called messenger RNA (mRNA) to produce an immune response. The vaccine transfects molecules of synthetic RNA into immunity cells. Once inside the immune cells, the vaccine's RNA functions as mRNA, causing the cells to build the foreign protein that would normally be produced by a pathogen (such as a virus) or by a cancer cell. These protein molecules stimulate an adaptive immune response which teaches the body how to identify and destroy the corresponding pathogen or cancer cells. The delivery of mRNA is achieved by a co-formulation of the molecule into lipid nanoparticles which protect the RNA strands and helps their absorption into the cells.Reactogenicity, the property of a vaccine of being able to produce common, "expected" adverse reactions, is similar to that of conventional, non-RNA, vaccines. People susceptible to an autoimmune response may have an adverse reaction to RNA vaccines. The advantages of RNA vaccines over traditional protein vaccines are superior design and production speed, lower cost of production, and the induction of both cellular as well as humoral immunity. A disadvantage in the Pfizer-BioNTech mRNA vaccine for COVID-19 is that it requires ultracold storage before distribution.In RNA therapeutics, mRNA vaccines have attracted considerable interest as COVID-19 vaccines. By December 2020, there were two novel mRNA vaccines for COVID-19 that had completed the required eight-week period post-final human trials and were awaiting emergency use authorization (EUA): the Moderna COVID-19 vaccine (mRNA-1273) and the Pfizer–BioNTech COVID-19 vaccine (BNT162b2). On 2 December 2020, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) became the first medicines regulator to approve an mRNA vaccine, authorizing the Pfizer–BioNTech COVID-19 vaccine (Comirnaty) for widespread use. On 11 December 2020, the US Food and Drug Administration (FDA) issued an EUA for the Pfizer-BioNTech COVID-19 vaccine and the US Centers for Disease Control and Prevention (CDC) recommended its use in those aged 16 and older on 12 December 2020. On 19 December 2020, the CDC recommended the use of the Moderna COVID-19 vaccine in adults after the FDA granted an EUA.The use of RNA in a vaccine has been the basis of substantial misinformation circulated via social media, wrongly claiming that the use of RNA alters a person's DNA, or emphasizing the technology's previously unknown safety record, while ignoring the more recent accumulation of evidence from trials involving tens of thousands of people.
Omni är politiskt obundna och oberoende. Vi strävar efter att ge fler perspektiv på nyheterna. Har du frågor eller synpunkter kring vår rapportering? Kontakta redaktionen